Journal
PRENATAL DIAGNOSIS
Volume 33, Issue 11, Pages 1050-1053Publisher
WILEY
DOI: 10.1002/pd.4195
Keywords
-
Categories
Funding
- Ariosa Diagnostics
- Ariosa Diagnostics Inc., San Jose, CA, USA
Ask authors/readers for more resources
ObjectivePilot studies have suggested the amount of cell-free fetal DNA (cffDNA) in the maternal serum is increased in pregnancies complicated by placenta accreta. Our objective was to determine if levels of cffDNA can predict invasive placentation. MethodsWe enrolled women with antenatally suspected placenta accreta compared with gestational age-matched cases of placenta previa and women with prior cesarean deliveries (CDs) and normal placentation. The fetal fraction of cffDNA was quantified using DANSR as compared with total DNA. Patient characteristics were compared between the three groups using ANOVA, and linear regression was used to compare the fraction of cffDNA between pathologically confirmed cases of placenta accreta, placenta previa and normal placentation. ResultsTwenty women were enrolled, (seven cases of placenta accreta, six cases of placenta previa and seven cases of normal placentation with prior CD). The groups did not differ by maternal weight, placental weight, number of prior CD or years from prior CD. The mean fraction of cffDNA did not differ significantly by group when controlling for the aforementioned factors (accreta=19.1%, previa=27.2%, prior CD=28.9%, p=0.26), nor did the median (accreta=17.0%, previa=30.1%, prior CD=22.7%). ConclusionsWe could not confirm diagnostic benefit. Further investigation of other biomarkers including placental mRNA is warranted. (c) 2013 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available